First Manhattan
CARM

First Manhattan’s Carisma Therapeutics CARM Stock Holding History

First Manhattan’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,100
Closed -$37K – 1551
2022
Q1 		$37K Hold
3,100
– – ﹤0.01% 1054
2021
Q4 		$50K Hold
3,100
– – ﹤0.01% 995
2021
Q3 		$49K Hold
3,100
– – ﹤0.01% 997
2021
Q2 		$286K Hold
3,100
– – ﹤0.01% 668
2021
Q1 		$161K Buy
+3,100
New +$146K ﹤0.01% 744

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

First Manhattan's CARM Position: Q2 2022 in Review

First Manhattan sold out of Carisma Therapeutics (CARM) in Q2 2022, closing a stake of 3,100 shares — an estimated $37K sold.

First Manhattan first reported a position in CARM in Q1 2021 and held it in 5 quarters. The position peaked at $286K in Q2 2021. 73 funds tracked by Wall St. Rank hold CARM as of Q2 2022.

  • First Manhattan reported no remaining Carisma Therapeutics position as of Q2 2022 after selling out during the quarter.
  • First Manhattan sold 3,100 Carisma Therapeutics shares in Q2 2022, an estimated $37K.
  • First Manhattan first reported a position in Carisma Therapeutics in Q1 2021 and held it in 5 quarters.
  • First Manhattan's Carisma Therapeutics position peaked at $286K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2022.

Based on First Manhattan's 13F filing for Q2 2022, filed 15 Aug 2022.